CYP2C19 and metabolic dysfunction-associated steatotic liver disease: Based on our findings of decreased CYP2C19 expression and the clinical actionability of CYP2C19*2, it is logical to suggest that NAFLD patients are at increased risk for clopidogrel treatment failure and therefore more cardiovascular morbidity.